Takeda Pharmaceutical Company Limited

4502

JP3463000004

Takeda Pharmaceutical Company Limited specializes in the development, manufacturing and marketing of pharmaceutical products especially for metabolic and cardiovascular diseases, cancers and central nervous systems troubles. The activity is organized around 2 areas: - sale of drugs and consumer care products; - services. Net sales are distributed geographically as follows: Japan (17.5%), Asia (5%), the United States (49%), Europe and Canada (20.8%), Latin America (3.8%), Russia and CIS (1.8%) and other (2.1%).

Sector

Pharmaceuticals

Calendar

26/06/2024 - Shareholders Meeting

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Takeda Pharmaceutical Company Limited

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

4,070 JPY

Average target price

4,779 JPY

Spread / Average Target

+17.42%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
TAKEDA PHARMACEUTICAL COMPANY LIMITED	+1.01%	40.87B
ELI LILLY AND COMPANY	+32.36%	698B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.40%	358B
MERCK & CO., INC.	+19.46%	328B
ABBVIE INC.	+3.50%	283B
ASTRAZENECA PLC	+16.34%	238B
NOVARTIS AG	+6.68%	203B
ROCHE HOLDING AG	-9.08%	198B
AMGEN INC.	+8.62%	165B

Other Pharmaceuticals

Delayed Japan Exchange Other stock markets 05:57:10 10/05/2024 am IST			5-day change	1st Jan Change
4,089 ^JPY	+0.47%		-0.73%	+1.01%

09/05	Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup	DJ
09/05	Sector Update: Health Care Stocks Steady Pre-Bell Thursday	MT

Health Care Climbs as Obesity-Drug Optimism Returns - Health Care Roundup	10/05	DJ
Sector Update: Health Care Stocks Steady Pre-Bell Thursday	09/05	MT
Takeda Pharmaceutical's Fiscal Q1 Core Earnings Decline, Revenue Increases; Fiscal 2024 Outlook Issued	09/05	MT
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss -- Update	09/05	DJ
Takeda Pharmaceutical Projects Lower Annual Profit After Quarterly Loss	09/05	DJ
Japan's Takeda Pharma says full-year profit slumps 56%	09/05	RE
Takeda Pharmaceutical Company Limited Announces Demise of its Board Member, Olivier Bohuon	09/05	CI
Takeda Pharmaceutical Company Limited Provides Earnings Guidance for the Full Year of 2024	09/05	CI
Takeda Pharmaceutical Company Limited Declares Dividend for the Year Ended March 31, 2024, Payable June 27, 2024; Provides Dividend Guidance for the Second Quarter-End and Year-End of Fiscal Year Ending March 31, 2025	09/05	CI
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion	30/04	RE
EU Panel Backs Approval of Takeda’s Colorectal Cancer Drug	26/04	MT
Hutchmed notes CHMP's positive opinion for fruiquintinib approval	26/04	AN
European Medicines Agency Committee Backs Approval of Takeda's Fruquintinib to Treat Colorectal Cancer	26/04	MT
Takeda Receives Positive Chmp Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer	26/04	CI
Takeda Teams Up With Astellas Pharma, Sumitomo Mitsui Banking to Support Incubation of Early Drug Discovery Programs	22/04	MT
Takeda, Astellas and Sumitomo Mitsui Banking Announce Master Agreement to Establish Joint Venture Company for Incubation of Early Drug Discovery Programs	22/04	CI
Takeda Pharmaceutical Wins US FDA Approval for Subcutaneous Administration of Crohn’s Disease Therapy	22/04	MT
Sector Update: Health Care Stocks Steady Pre-Bell Friday	19/04	MT
Takeda Pharmaceutical Receives FDA Approval for Single-Dose Injection Crohn's Disease Treatment	19/04	MT
U.S. Food and Drug Administration Approves Subcutaneous Administration of Takeda Pharmaceutical Company Limited's ENTYVIO (Vedolizumab) for Maintenance Therapy in Moderately to Severely Active Crohn's Disease	19/04	CI
Takeda Says FDA Has Approved Subcutaneous Entyvio for Crohn's Disease	19/04	DJ
Takeda Pharmaceutical to Issue 2nd Hybrid Bonds in Mid-2024 to Refinance 500 Billion Yen 1st Hybrid Bonds	16/04	MT
Alinamin Pharmaceutical Co., Ltd. acquired Nihon Pharmaceutical Co., Ltd. from Takeda Pharmaceutical Company Limited.	01/04	CI
Takeda Pharmaceutical Says Adzynma Gains Approval in Japan to Treat Blood Clotting Disorder	26/03	MT
Takeda Pharmaceuticals U.S.A, Inc. Announces Approval of Adzynma Intravenous Injection 1500 (Apadamtase Alfa) in Japan for Patients with Congenital Thrombotic Thrombocytopenic Purpura	26/03	CI